Cystic Fibrosis Transmembrane Conductance Regulator Genotype, Not Circulating Catecholamines, Influences Cardiovascular Function in Patients with Cystic Fibrosis
AuthorBisch, Alexander L
Wheatley, Courtney M
Baker, Sarah E
Peitzman, Elizabeth R
Van Iterson, Erik H
Laguna, Theresa A
Morgan, Wayne J
Snyder, Eric M
AffiliationUniv Arizona, Arizona Resp Ctr
cystic fibrosis transmembrane conductance regulator
MetadataShow full item record
PublisherSAGE PUBLICATIONS LTD
CitationBisch, A. L., Wheatley, C. M., Baker, S. E., Peitzman, E. R., Van Iterson, E. H., Laguna, T. A., ... & Snyder, E. M. (2019). Cystic Fibrosis Transmembrane Conductance Regulator Genotype, Not Circulating Catecholamines, Influences Cardiovascular Function in Patients with Cystic Fibrosis. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 13, 1179548419835788.
RightsCopyright © The Author(s) 2019. Article reuse guidelines: sagepub.com/journals-permissions. Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/).
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at email@example.com.
AbstractBACKGROUND: Cystic fibrosis (CF) is a genetic disease affecting multiple organ systems of the body and is characterized by mutation in the gEne coding for the cystic fibrosis transmembrane conductance regulator (CFTR). Previous work has shown that a single dose of a beta-agonist increases cardiac output (Q) and stroke volume (SV) and decreases systemic vascular resistance (SVR) in healthy subjects. This effect is attenuated in patients with CF; however, the mechanism is unknown. Potential explanations for this decreased cardiovascular response to a beta-agonist in CF include inherent cardiovascular deficits secondary to the CFTR mutation, receptor desensitization from prolonged beta-agonist use as part of clinical care, or inhibited drug delivery to the bloodstream due to mucus buildup in the lungs. This study sought to determine the effects of endogenous epinephrine (EPI) and norepinephrine (NE) on cardiovascular function in CF and to evaluate the relationship between cardiovascular function and CFTR F508del mutation. METHODS: A total of 19 patients with CF and 31 healthy control subjects completed an assessment of Q (C2H2 rebreathing), SV (calculated from Q and heart rate [HR]), Q and SV indexed to body surface area (BSA. Ql. and SVI. respectively). SVR (through assessment of Q and mean arterial blood pressure [MAP]). and HR (from 12-lead electrocardiogram [ECG]) at rest along with plasma measures of EPI and NE. We compared subjects by variables of cardiovascular function relative to EPI and NE, and also based on genetic variants of the F508del mutation (homozygous deletion for F508del. heterozygous deletion for F508del, or no deletion of F508del). RESULTS: Cystic fibrosis patients demonstrated significantly lower BSA (CF = 1.71 +/- 0.05 m(2) vs healthy = 1.84 +/- 0.04 m(2), P = .03) and SVI (CF = 30.6 +/- 2.5 mL/beat/m(2) vs healthy = 39.9 +/- 2.5 mL/beat/m(2) , P = .02) when compared with healthy subjects. Cystic fibrosis patients also demonstrated lower Q (CF = 4.58 +/- 0.36 L/min vs healthy = 5.71 +/- 0.32 L/min, P = .03) and SV (CF = 54 +/- 5.5 mL/beat vs healthy = 73.3 +/- 4.5 mL/beat. P = .01), and a higher HR (CF = 93.2 +/- 3.9 bpm vs healthy = 80.5 +/- 2.7 bpm, P < .01) and SVR (CF = 2082 +/- 156 dynes(*)s/cm(-5) vs healthy = 1616 +/- 74 dynes*s/cm(-5), P= .01) compared with healthy subjects. Furthermore. CF patients demonstrated a lower SV (P < .01) corrected for NE when compared with healthy subjects. No significant differences were seen in HR or Q relative to NE. or SVR relative to EPI. Differences were seen in SV(F-(2,F-14) = 7.982, P < .01) and SV index (F-(2(,14)) = 2.913, P = .08) when patients with CF were stratified according to F508del mutation (number of deletions). CONCLUSIONS: Individuals with CF have lower cardiac and peripheral hemodynamic function parameters at rest. Furthermore, these results suggest that impairment in cardiovascular function is likely the result of F508del CFTR genotype, rather than receptor desensitization or inhibited drug delivery.
NoteOpen access journal
VersionFinal published version
SponsorsNIH [HL 108962-01]
Except where otherwise noted, this item's license is described as Copyright © The Author(s) 2019. Article reuse guidelines: sagepub.com/journals-permissions. Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/).
- Impaired cardiac and peripheral hemodynamic responses to inhaled β₂-agonist in cystic fibrosis.
- Authors: Van Iterson EH, Karpen SR, Baker SE, Wheatley CM, Morgan WJ, Snyder EM
- Issue date: 2015 Sep 5
- Augmentation of Cystic Fibrosis Transmembrane Conductance Regulator Function in Human Bronchial Epithelial Cells via SLC6A14-Dependent Amino Acid Uptake. Implications for Treatment of Cystic Fibrosis.
- Authors: Ahmadi S, Wu YS, Li M, Ip W, Lloyd-Kuzik A, Di Paola M, Du K, Xia S, Lew A, Bozoky Z, Forman-Kay J, Bear CE, Gonska T
- Issue date: 2019 Dec
- Efficacy and Safety of CFTR Corrector and Potentiator Combination Therapy in Patients with Cystic Fibrosis for the F508del-CFTR Homozygous Mutation: A Systematic Review and Meta-analysis.
- Authors: Wu HX, Zhu M, Xiong XF, Wei J, Zhuo KQ, Cheng DY
- Issue date: 2019 Feb
- Pharmacological Correction of Cystic Fibrosis: Molecular Mechanisms at the Plasma Membrane to Augment Mutant CFTR Function.
- Authors: Arora K, Naren AP
- Issue date: 2016
- Cystic fibrosis transmembrane conductance regulator (CFTR) allelic variants relate to shifts in faecal microbiota of cystic fibrosis patients.
- Authors: Schippa S, Iebba V, Santangelo F, Gagliardi A, De Biase RV, Stamato A, Bertasi S, Lucarelli M, Conte MP, Quattrucci S
- Issue date: 2013